Developing vaccines and antibody treatments for specific viral infections
Official title: Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPP
Funded at Washington University · NIH-10863691 · Data updated 2026-11-12
This study is working on new vaccines and treatments for certain viruses that can make people sick, and it's designed to help anyone who might be at risk of these infections by finding better ways to protect and treat them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 11, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $44,108,652 |
| NIH project number | 1U19AI181984-01 |
| Project ID | NIH-10863691 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit include individuals at risk for infections caused by the targeted viruses, such as those in endemic areas or with compromised immune systems.
✕Less likely to help
Patients who are not at risk for these specific viral infections may not receive any benefit from this research.
What this research studies
This research focuses on creating prototype vaccines and monoclonal antibody treatments for viruses from the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families. The approach involves using reverse vaccinology to understand how these viruses enter cells and how the immune system can be effectively targeted. By studying both human and bat viruses, the research aims to develop rapid response strategies for emerging viral threats. Patients may benefit from new preventive and therapeutic options against these viral infections.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines and treatments for viral infections that currently have limited options.
How similar studies have gone: Previous research has shown promise in developing vaccines and treatments for similar viral families, indicating a potential for success in this novel approach.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Whelan, Sean Pj — Washington University
- Study coordinator: Whelan, Sean Pj
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.